Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol in Refractory Hypertension
NCT02357004Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- Feb 2015
- Primary completion
- Jan 2020
- Modality
- Small Molecules
01
Overview
Randomised trial of carvedilol in hypertension (HTN) (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Percentage of subjects who achieve BP control (<140/90 mm Hg) at 8 weeks. Planned start Feb 2015; status: withdrawn.
02
Drugs
carvedilol
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02357004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02357004.